Table 3.
Second end point data comparison
| Number | group | case | Follow-up time/HPVpersistent infection or re-infection cases | |||
|---|---|---|---|---|---|---|
|
| ||||||
| 3 months | 6 months | 12 months | 24 months | |||
| 1 | p16+/ki67+ | 509 | 267 (52.45%) | 198 (38.90%) | 114 (22.40%) | 99 (19.45%) |
| 2 | P16+/ki67- | 601 | 454 (75.54%) | 381 (63.40%) | 135 (22.46%) | 83 (13.81%) |
| 3 | P16-/ki67+ | 403 | 201 (49.88%) | 198 (49.13%) | 66 (16.38%) | 50 (12.41%) |
| 4 | P16-/ki67- | 387 | 200 (51.68%) | 164 (42.38%) | 86 (22.22%) | 34 (8.79%) |
| Statistical index | ||||||
In all four groups, there was a significant change in HPV infection or re-infection rate with prolonged follow-up time. Although there was no significant regression in the period of 3 months to 1 year, in the cases of more than one year, significantly lower trends were observed in group 4. At 24 months follow-up time, cases of HPV persistent infection or re-infection rate of each group were statistically significant, all P values were <0.05.